Your browser is no longer supported. Please, upgrade your browser.
BLUE bluebird bio, Inc. daily Stock Chart
BLUE [NASD]
bluebird bio, Inc.
Index- P/E- EPS (ttm)-14.96 Insider Own0.50% Shs Outstand55.59M Perf Week7.55%
Market Cap4.34B Forward P/E- EPS next Y-12.12 Insider Trans-1.25% Shs Float55.38M Perf Month-6.34%
Income-827.80M PEG- EPS next Q-2.64 Inst Own91.10% Short Float13.64% Perf Quarter37.61%
Sales54.10M P/S80.15 EPS this Y-34.00% Inst Trans-2.14% Short Ratio5.04 Perf Half Y-29.67%
Book/sh20.16 P/B3.17 EPS next Y4.90% ROA-46.20% Target Price- Perf Year-52.24%
Cash/sh13.44 P/C4.76 EPS next 5Y- ROE-60.10% 52W Range38.95 - 143.98 Perf YTD-27.08%
Dividend- P/FCF- EPS past 5Y-50.80% ROI-63.40% 52W High-55.56% Beta2.36
Dividend %- Quick Ratio5.20 Sales past 5Y11.90% Gross Margin93.40% 52W Low64.29% ATR3.41
Employees1153 Current Ratio5.20 Sales Q/Q75.20% Oper. Margin- RSI (14)53.25 Volatility6.30% 5.43%
OptionableYes Debt/Eq0.00 EPS Q/Q-21.80% Profit Margin- Rel Volume0.37 Prev Close66.16
ShortableYes LT Debt/Eq0.00 EarningsMay 11 BMO Payout- Avg Volume1.50M Price63.99
Recom1.80 SMA201.55% SMA503.53% SMA200-12.16% Volume547,364 Change-3.28%
May-13-20Initiated RBC Capital Mkts Outperform $100
Mar-27-20Upgrade Stifel Hold → Buy $70
Feb-19-20Downgrade Raymond James Strong Buy → Mkt Perform
Feb-19-20Downgrade Raymond James Outperform → Mkt Perform
Feb-03-20Upgrade Evercore ISI In-line → Outperform $86 → $100
Feb-03-20Resumed BofA/Merrill Buy $120
Dec-13-19Upgrade Oppenheimer Perform → Outperform $135
Nov-26-19Upgrade SVB Leerink Mkt Perform → Outperform $119
Nov-19-19Downgrade Evercore ISI Outperform → In-line $86
Nov-04-19Upgrade Wedbush Neutral → Outperform $131 → $124
Oct-01-19Initiated Stifel Hold $109
Aug-12-19Downgrade William Blair Outperform → Mkt Perform
Jun-18-19Upgrade Maxim Group Hold → Buy $160
May-15-19Downgrade Wedbush Outperform → Neutral $166 → $131
Mar-05-19Downgrade SVB Leerink Outperform → Mkt Perform
Feb-22-19Reiterated Cantor Fitzgerald Neutral $134 → $122
Dec-20-18Initiated Raymond James Strong Buy $165
Dec-06-18Downgrade Piper Jaffray Overweight → Neutral
Nov-14-18Upgrade Bernstein Mkt Perform → Outperform
Nov-05-18Upgrade Janney Neutral → Buy
Jul-07-20 12:08PM  
Jul-01-20 08:31AM  
Jun-23-20 08:39AM  
Jun-22-20 04:35PM  
Jun-18-20 02:28AM  
Jun-16-20 06:30AM  
Jun-12-20 01:49PM  
05:30AM  
05:30AM  
Jun-11-20 06:55AM  
Jun-10-20 11:30AM  
Jun-08-20 01:25AM  
Jun-05-20 05:35AM  
Jun-04-20 04:01PM  
Jun-03-20 04:05PM  
May-28-20 08:00AM  
May-27-20 10:35AM  
May-25-20 12:00PM  
May-22-20 11:10AM  
May-19-20 06:53PM  
07:19AM  
May-18-20 09:32PM  
02:54PM  
07:08AM  
07:00AM  
May-15-20 09:01AM  
May-14-20 09:00AM  
May-13-20 05:00PM  
10:41AM  
09:54AM  
07:45AM  
06:59AM  
May-12-20 01:40PM  
May-11-20 12:01PM  
11:22AM  
09:44AM  
08:25AM  
07:35AM  
07:00AM  
May-08-20 09:55AM  
07:30AM  
Apr-30-20 06:27AM  
Apr-29-20 08:00AM  
Apr-28-20 12:44PM  
Apr-20-20 08:51AM  
Apr-05-20 09:02PM  
Apr-03-20 06:34PM  
Mar-31-20 06:59AM  
06:51AM  
Mar-30-20 11:35AM  
Mar-26-20 12:36PM  
07:30AM  
Mar-19-20 11:30AM  
Feb-20-20 06:31AM  
Feb-19-20 07:59AM  
Feb-18-20 04:05PM  
Feb-17-20 06:17AM  
Feb-13-20 12:31PM  
Feb-05-20 08:00AM  
Feb-04-20 11:28AM  
Jan-28-20 05:26AM  
Jan-13-20 05:00AM  
Jan-08-20 05:50PM  
Jan-03-20 02:44PM  
Jan-02-20 05:01PM  
Dec-19-19 04:05PM  
07:11AM  
Dec-16-19 08:42AM  
Dec-12-19 07:34AM  
Dec-11-19 12:16PM  
09:41AM  
08:59AM  
Dec-10-19 09:48AM  
Dec-09-19 06:15PM  
04:30PM  
04:03PM  
03:51PM  
09:16AM  
Dec-07-19 02:00PM  
Dec-06-19 04:30PM  
04:16PM  
09:15AM  
Dec-03-19 08:52AM  
Dec-02-19 07:30AM  
Nov-27-19 03:28AM  
Nov-26-19 09:19AM  
Nov-19-19 10:46AM  
Nov-18-19 09:36AM  
Nov-12-19 07:00AM  
Nov-08-19 02:20PM  
Nov-07-19 06:08AM  
Nov-06-19 09:00AM  
Nov-05-19 08:58AM  
Nov-03-19 08:03AM  
Nov-02-19 12:00PM  
Oct-31-19 05:35PM  
04:05PM  
10:33AM  
Oct-23-19 04:30PM  
Oct-22-19 07:30AM  
bluebird bio, Inc., a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer. Its product candidates in severe genetic diseases include LentiGlobin, which is in various clinical studies for the treatment of transfusion-dependent ß-thalassemia and severe sickle cell disease; and Lenti-D that is in Phase II/III clinical trials for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder. The company's product candidates in oncology include bb2121 and bb21217, which are chimeric antigen receptor T (CAR T) cell product candidates for the treatment of multiple myeloma. It has a strategic collaboration with Celgene Corporation to discover, develop, and commercialize disease-altering gene therapies in oncology; and Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize various immune cell therapies for cancer. The company also has collaborations with Medigene AG to discover T cell receptor (TCR) product candidates in the field of cancer; Gritstone Oncology, Inc. to discover TCR product candidates in the field of cancer; TC BioPharm Limited to research and develop gamma delta CAR T cells directed at hematologic and solid tumor targets; and Novo Nordisk A/S to develop in vivo genome editing treatments for genetic diseases. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was founded in 1992 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Smith-Farrell JoanneChief Business OfficerJul 02Sale61.57382,34022,349Jul 07 05:17 PM
Leschly NickPresident and CEOJul 02Sale61.5744327,27799,904Jul 07 05:19 PM
Cole JasonChief Operating andJul 02Sale61.57382,34035,410Jul 07 05:18 PM
Davidson DavidChief Medical OfficerJul 02Sale61.57422,58639,850Jul 07 05:22 PM
Gregory Philip DChief Scientific OfficerJul 02Sale61.57593,63336,101Jul 07 05:15 PM
FINGER ALISON CECILYChief Commercial OfficerJul 02Sale61.57362,21727,133Jul 07 05:16 PM
Smith-Farrell JoanneChief Business OfficerJun 04Sale65.2317011,08922,387Jun 08 04:24 PM
WENTWORTH KORY JAMESPrincipal Accounting OfficerJun 04Sale65.2315410,04510,190Jun 08 04:24 PM
Davidson DavidChief Medical OfficerJun 02Sale64.03422,68939,892Jun 04 05:44 PM
Cole JasonChief Operating andJun 02Sale64.03382,43335,448Jun 04 05:44 PM
Smith-Farrell JoanneChief Business OfficerJun 02Sale64.03372,36922,557Jun 04 05:44 PM
Gregory Philip DChief Scientific OfficerJun 02Sale64.03593,77836,160Jun 04 05:43 PM
FINGER ALISON CECILYChief Commercial OfficerJun 02Sale64.04352,24127,169Jun 04 05:44 PM
Leschly NickPresident and CEOJun 02Sale64.0444428,433100,347Jun 04 05:44 PM
Smith-Farrell JoanneChief Business OfficerMay 04Sale50.1723211,63922,594May 05 04:05 PM
Smith-Farrell JoanneChief Business OfficerApr 06Sale43.7358325,49521,393Apr 08 04:12 PM
Baird William D IIIChief Financial OfficerFeb 13Sale90.601,254113,61213,746Feb 18 07:14 PM
Gregory Philip DChief Scientific OfficerJan 10Option Exercise50.5160030,30625,308Jan 14 05:33 PM
Gregory Philip DChief Scientific OfficerJan 10Sale94.0360056,41624,708Jan 14 05:33 PM
Leschly NickPresident and CEOJan 07Sale89.9710,163914,37756,712Jan 09 05:33 PM
Gregory Philip DChief Scientific OfficerJan 07Sale89.974,134371,94124,708Jan 09 05:33 PM
Davidson DavidChief Medical OfficerJan 07Sale89.973,297296,63528,319Jan 09 05:33 PM
Cole JasonChief Operating andJan 07Sale89.971,957176,07425,049Jan 09 05:33 PM
FINGER ALISON CECILYChief Commercial OfficerJan 07Sale89.971,04994,38018,148Jan 09 05:33 PM
WENTWORTH KORY JAMESPrincipal Accounting OfficerJan 07Sale89.9722320,0646,308Jan 09 05:33 PM
Smith-Farrell JoanneChief Business OfficerJan 07Sale89.9740836,70811,976Jan 09 05:33 PM
Gregory Philip DChief Scientific OfficerJan 06Sale86.6625021,66528,842Jan 08 05:13 PM
FINGER ALISON CECILYChief Commercial OfficerJan 03Sale84.9651743,92419,197Jan 07 05:02 PM
WENTWORTH KORY JAMESPrincipal Accounting OfficerDec 19Sale92.5939736,7586,449Dec 23 05:00 PM
Gregory Philip DChief Scientific OfficerDec 17Option Exercise50.511,80090,91830,892Dec 19 04:54 PM
Gregory Philip DChief Scientific OfficerDec 17Sale94.311,800169,74929,092Dec 19 04:54 PM
Gregory Philip DChief Scientific OfficerDec 05Sale80.5725020,14329,092Dec 09 05:01 PM
Gregory Philip DChief Scientific OfficerNov 05Sale81.9525020,48829,342Nov 07 04:11 PM
Gregory Philip DChief Scientific OfficerOct 07Sale89.0725022,26729,592Oct 09 04:14 PM
Davidson DavidChief Medical OfficerSep 10Option Exercise50.512,060104,05133,676Sep 11 04:29 PM
Davidson DavidChief Medical OfficerSep 10Sale100.162,060206,32431,616Sep 11 04:29 PM
Davidson DavidChief Medical OfficerSep 09Option Exercise50.513,000151,53034,616Sep 11 04:29 PM
Davidson DavidChief Medical OfficerSep 09Sale100.113,000300,34031,616Sep 11 04:29 PM
Gregory Philip DChief Scientific OfficerSep 05Option Exercise50.5160030,30630,692Sep 09 04:54 PM
Gregory Philip DChief Scientific OfficerSep 05Sale101.2085086,01829,842Sep 09 04:54 PM
Walsh Jeffrey T.Chief Strategy OfficerAug 20Option Exercise24.4750012,23541,421Aug 21 04:06 PM
Walsh Jeffrey T.Chief Strategy OfficerAug 20Sale124.0050062,00040,921Aug 21 04:06 PM
Gregory Philip DChief Scientific OfficerAug 08Option Exercise75.6070052,92031,042Aug 12 04:08 PM
Gregory Philip DChief Scientific OfficerAug 08Sale124.03950117,82430,092Aug 12 04:08 PM
Davidson DavidChief Medical OfficerAug 06Option Exercise50.515,060255,58136,676Aug 08 04:19 PM
Davidson DavidChief Medical OfficerAug 06Sale116.085,060587,38931,616Aug 08 04:19 PM
Gregory Philip DChief Scientific OfficerAug 05Option Exercise50.5160030,30631,192Aug 07 04:14 PM
Gregory Philip DChief Scientific OfficerAug 05Sale116.9385099,39330,342Aug 07 04:14 PM